Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
In children with B‐thalassemia, survival comes at the cost of repeated transfusions. The treatment for iron overload is an early and effective chelation. The approved iron chelators in the present day scenario are only three as desferrioxamine, deferiprone and deferasirox. Present study was aimed to study safety and efficacy of Deferasirox as an iron chelator in children with B‐thalassemia major. Present study was single‐center, prospective Interventional study conducted in children of age 2‐18 years, having Serum Ferritin level >1000 ng mL, already on Deferasirox therapy, whose medical records are available, Deferasirox was started with initial dose of 30 mg kg orally once daily doses calculated to the nearest whole tablet (500 mg).The dose was increased to 35 mg kg day if serum ferritin remained unchanged or increased 3 month after Deferasirox therapy. The maximum dose is 40 mg kg day. The total number of children in this study was 30. There were 15 (50%) girls and the boys were 15 (50%) of the total sample population. The mean age of studied population was 8.29±4.883 years, including patients of 2‐10 years (20) and 11‐18 years (10). Hemoglobin at diagnosis(g/dL) was <7 in majority of cases (93.3%). Majority of the patients (40%) were diagnosed with B thalassemia major between the age of 6 and 12 months. A significant decrease in serum ferritin levels was observed in all age groups at the end of 1 year of treatment with Deferasirox. (p‐value is 0.018). Only two patients showed adverse drug reactions (ADRs) out of 30 patients. Most common ADRs observed were Rash (n = 1) and nose bleeding (n = 1). A significant decrease in the mean serum ferritin levels was observed with deferasirox treatment. Deferasirox is relatively well tolerated among these patients.
How to cite this article:
Shweta Gupta, Parag Mahankar and Ramdas Dahiphale. Study to Assess Safety and Efficacy of Deferasirox as an Iron Chelator in Children with B‐Thalassemia Major.
DOI: https://doi.org/10.36478/10.59218/makrjms.2024.5.124.127
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2024.5.124.127